Related Experiment Videos
West Nile virus vaccines.
Roy A Hall1, Alexander A Khromykh
1Department of Microbiology and Parasitology, The University of Queensland, Brisbane, Queensland 4072, Australia. roy.hall@mailbox.uq.edu.au
Expert Opinion on Biological Therapy
|July 23, 2004
Summary
West Nile virus (WNV) is a growing global threat, prompting diverse vaccine development strategies. Research explores inactivated, DNA, chimeric, and cross-protective vaccines to combat WNV outbreaks in humans and animals.
Area of Science:
- Virology
- Immunology
- Vaccinology
Background:
- West Nile virus (WNV) is an emerging mosquito-borne flavivirus causing significant human and animal disease outbreaks globally.
- Virulent WNV strains have led to major health concerns in Europe, the Middle East, and North America over the past decade.
Purpose of the Study:
- To review and assess various vaccine development approaches for West Nile virus.
- To evaluate the efficacy and safety of different WNV vaccine candidates for both veterinary and human use.
Main Methods:
- Review of traditional and novel vaccine strategies including formalin-inactivated, DNA, chimeric, and cross-protective vaccines.
- Assessment of vaccine protection in various animal models (mice, horses, birds) and ongoing human trials.
Main Results:
- A formalin-inactivated WNV vaccine is approved for horses.
- DNA vaccines show protective efficacy in mice, horses, and birds.
- Live attenuated yellow fever WNV chimeric vaccines are successful in animals and in human trials.
- Immunization with Kunjin virus (an Australian WNV variant) confers protection against virulent North American WNV strains.
Conclusions:
- Multiple vaccine candidates demonstrate protective immunity against West Nile virus.
- Consideration of efficacy, safety, logistical, economic, and environmental factors is crucial for vaccine approval and distribution.